Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.67 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.67 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.67 |
| ▸ | DPP4 | P27487 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.67 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.67 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.67 |
| ▸ | GAPDH | P04406 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | STAT6 | P42226 | 1/20 | 0.67 |
| ▸ | PI4KA | P42356 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.67 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.67 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.67 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.67 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6261501 | 1.00 | ADORA2A (0.67) | ADORA2AADORA2BADORA3ADORA1DPP4 | |
| SCHEMBL29705813 | 1.00 | ADORA2A (0.67) | ADORA2AADORA2BADORA3ADORA1DPP4 | |
| SCHEMBL8007481 | 1.00 | ADORA2A (0.67) | ADORA2AADORA2BADORA3ADORA1DPP4 | |
| SCHEMBL24872346 | 0.99 | ADORA1 (0.66) | ADORA2AADORA2BADORA3ADORA1DPP4 | |
| SCHEMBL25284573 | 0.99 | ADORA1 (0.66) | ADORA2AADORA2BADORA3ADORA1DPP4 | |
| SCHEMBL25284572 | 0.99 | ADORA1 (0.66) | ADORA2AADORA2BADORA3ADORA1DPP4 | |
| SCHEMBL4456272 | 0.99 | ADORA1 (0.66) | ADORA2AADORA2BADORA3ADORA1DPP4 | |
| SCHEMBL24968581 | 0.99 | ADORA1 (0.66) | ADORA2AADORA2BADORA3ADORA1DPP4 | |
| SCHEMBL4456275 | 0.99 | ADORA1 (0.66) | ADORA2AADORA2BADORA3ADORA1DPP4 | |
| SCHEMBL30605195 | 0.99 | ADORA1 (0.66) | ADORA2AADORA2BADORA3ADORA1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188477-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDE HAVING RNAi ACTIVITY | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-06-12 | — | — | US | disclosed |
| US-20250188478-A1 | siRNA SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR 2 | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-06-12 | — | — | US | disclosed |
| WO-2025110249-A1 | COMPOSITION FOR NUCLEOTIDE SEQUENCE EDITING, AND NUCLEOTIDE SEQUENCE EDITING METHOD USING SAME | 国立大学法人 広島大学 | 2025-05-30 | — | — | WO | disclosed |
| WO-2025063238-A1 | SIRNA FOR SUPPRESSING EXPRESSION OF PHOSPHOLAMBAN | 第一三共株式会社 | 2025-03-27 | — | — | WO | disclosed |
| WO-2025063239-A1 | SIRNA CAPABLE OF SUPPRESSING EXPRESSION OF α-SYNUCLEIN | 第一三共株式会社 | 2025-03-27 | — | — | WO | disclosed |
| EP-4495240-A1 | SIRNA FOR SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR-2 | Daiichi Sankyo Company, Limited (JP) | 2025-01-22 | — | — | EP | disclosed |
| WO-2023176862-A1 | siRNA FOR SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR-2 | 第一三共株式会社 | 2023-09-21 | — | — | WO | disclosed |
| WO-2023176863-A1 | CHEMICALLY-MODIFIED OLIGONUCLEOTIDE HAVING RNAI ACTIVITY | 第一三共株式会社 | 2023-09-21 | — | — | WO | disclosed |
| US-20220378920-A1 | CONJUGATE OF GalNAc-OLIGONUCLEOTIDE FOR DELIVERY TO LIVER AND MANUFACTURING METHOD THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-12-01 | — | — | US | disclosed |
| US-20220364086-A1 | ANTISENSE OLIGONUCLEOTIDE CAPABLE OF ALTERING SPLICING OF DUX4 pre-mRNA | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-11-17 | — | — | US | disclosed |
| EP-3998108-A1 | ANTISENSE OLIGONUCLEOTIDE CAPABLE OF ALTERING SPLICING OF DUX4 PRE-MRNA | Daiichi Sankyo Company, Limited (JP) | 2022-05-18 | — | — | EP | disclosed |
| WO-2021112106-A1 | XERODERMA PIGMENTOSUM GROUP F THERAPEUTIC AGENT | 第一三共株式会社 | 2021-06-10 | — | — | WO | disclosed |
| US-6022691-A | DETECTING A CHEMICAL OR DRUG IN A SAMPLE; CONTACTING THE SAMPLE WITH A NUCLEOTIDE SEQUENCE WHICH HYBRIDIZES TO A SPECIFIC TARGET MOLECULE, DETECTING BINDING OF NUCLEOTIDE SEQUENCES, BINDING IS INDICATION OF DRUG OR CHEMICAL PRESENT | ISIS PHARMACEUTICALS, INC. (US) | 2000-02-08 | — | — | US | disclosed |
| US-5747253-A | Combinatorial oligomer immunoabsorbant screening assay for transcription factors and other biomolecule binding | ISIS PHARMACEUTICALS, INC. (US) | 1998-05-05 | — | — | US | disclosed |
| US-5698391-A | DETERMINATION OF TARGET PROPERTY; BIOSYNTHESIS CYCLES | ISIS PHARMACEUTICALS, INC. (US) | 1997-12-16 | — | — | US | disclosed |
| US-5686242-A | Determination of oligonucleotides for therapeutics, diagnostics and research reagents | ISIS PHARMACEUTICALS, INC. (US) | 1997-11-11 | — | — | US | disclosed |
| US-5672472-A | REPEATED ENZYME-FREE SYNTHESIS OF INCREASINGLY SIMPLIFIED SETS OF OLIGONUCLEOTIDES WHILE DETERMINING WHICH SEQUENCE HAS HIGHEST TARGET ACTIVITY | ISIS PHARMACEUTICALS, INC. (US) | 1997-09-30 | — | — | US | disclosed |
| US-5587471-A | ANALYZING AND EVALUATING PHOSPHORUS BEARING MONOMERIC UNITS AS TO THEIR SUITABILITY, COUPLING EFFICIENCY, IN PREPARING RANDOM OLIGOMER LIBRARIES; COMBINATORIAL CHEMISTRY | ISIS PHARMACEUTICALS, INC. (US) | 1996-12-24 | — | — | US | disclosed |
| WO-1995018868-A1 | RANDOM OLIGONUCLEOTIDE LIBRARIES AND METHODS OF MAKING THE SAME | ISIS PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
| WO-1994021825-A1 | COMBINATORIAL OLIGOMER IMMUNOABSORBANT SCREENING ASSAY FOR TRANSCRIPTION FACTORS AND OTHER BIOMOLECULE BINDING | ISIS PHARMACEUTICALS, INC. (US) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188478-A1 | siRNA SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR 2 | TFRC, FOLR2, FTH1 | ADORA2A 3422/4885ADORA2B 3863/4885ADORA3 3807/4885 |
| US-20220378920-A1 | CONJUGATE OF GalNAc-OLIGONUCLEOTIDE FOR DELIVERY TO LIVER AND MANUFACTURING METHOD THEREOF | CSGALNACT1, GALNT6, GALNT14 | ADORA2A 2233/4885ADORA2B 1496/4885ADORA3 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.